Gefitinib (250mg) Uses, Benefits, Importance, Price and More......

GEFISTERIS 250

Gefitinib (250mg)

GEFISTERIS 250, containing 250mg of Gefitinib, is a cutting-edge medication designed for the treatment of non-small cell lung cancer (NSCLC). As a targeted therapy, it specifically attacks cancer cells by inhibiting the tyrosine kinase enzyme, which is often overactive in NSCLC patients.

How GEFISTERIS 250 Works Gefitinib, the active ingredient in GEFISTERIS 250, blocks the tyrosine kinase enzyme associated with the epidermal growth factor receptor (EGFR). This receptor is frequently mutated in NSCLC cells, driving their growth and spread. By inhibiting this pathway, GEFISTERIS 250 effectively slows down or stops the proliferation of cancer cells.

Benefits of GEFISTERIS 250

• Targeted Action: Directly targets and inhibits the growth of cancer cells, reducing the progression of the disease.
• Improved Outcomes: Has been shown to improve survival rates and quality of life in patients with NSCLC who have specific EGFR mutations.
• Oral Administration: Convenient oral tablet form, allowing for easy and comfortable treatment at home.

Why Choose GEFISTERIS 250?

GEFISTERIS 250 is chosen for its targeted approach in treating NSCLC, making it an effective option for patients with EGFR mutation-positive tumors. Its ability to specifically target cancer cells minimizes the impact on healthy cells, reducing side effects compared to traditional chemotherapy.

Usage and Dosage GEFISTERIS 250 is typically taken once daily or as prescribed by an oncologist. Patients should undergo testing for EGFR mutations to determine if GEFISTERIS 250 is the most appropriate treatment for their condition.

Safety and Precautions While GEFISTERIS 250 is effective for treating NSCLC, it can cause side effects such as diarrhea, rash, and liver function abnormalities. Regular monitoring and communication with a healthcare provider are essential to manage these potential side effects and ensure the effectiveness of the treatment.

Conclusion GEFISTERIS 250 represents a significant advancement in the treatment of non-small cell lung cancer, offering hope and improved outcomes for patients with EGFR mutation-positive NSCLC. With its targeted approach and convenient administration, GEFISTERIS 250 is an essential component of modern oncology, providing a critical tool in the fight against lung cancer.

A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  For further information:  EMAIL:  info@sterispharma.com  / contact@sterispharma.com     CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668   BUY NOW